CD33 and acute myeloid leukemia: Recently, the platform was applied to generate anti-CD33 CAR T cells by using the hyperactive SB100X transposase and the pT4 vector, which showed improved transduction efficiency compared to SB11 and pT systems and in vivo activity toward chemotherapy resistant/residual AML cells (92).